SG10201805411YA - Chimeric antigen receptors - Google Patents

Chimeric antigen receptors

Info

Publication number
SG10201805411YA
SG10201805411YA SG10201805411YA SG10201805411YA SG10201805411YA SG 10201805411Y A SG10201805411Y A SG 10201805411YA SG 10201805411Y A SG10201805411Y A SG 10201805411YA SG 10201805411Y A SG10201805411Y A SG 10201805411YA SG 10201805411Y A SG10201805411Y A SG 10201805411YA
Authority
SG
Singapore
Prior art keywords
chimeric antigen
antigen receptors
antigen
cell
polypeptides
Prior art date
Application number
SG10201805411YA
Inventor
Stewart Abbot
Bitao Liang
Tianjian Li
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of SG10201805411YA publication Critical patent/SG10201805411YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

CHIMERIC ANTIGEN RECEPTORS Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer. [Figure No. 1]
SG10201805411YA 2012-12-20 2013-12-19 Chimeric antigen receptors SG10201805411YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740113P 2012-12-20 2012-12-20
US201361779925P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201805411YA true SG10201805411YA (en) 2018-08-30

Family

ID=50979209

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504855WA SG11201504855WA (en) 2012-12-20 2013-12-19 Chimeric antigen receptors
SG10201805411YA SG10201805411YA (en) 2012-12-20 2013-12-19 Chimeric antigen receptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201504855WA SG11201504855WA (en) 2012-12-20 2013-12-19 Chimeric antigen receptors

Country Status (12)

Country Link
US (3) US10150816B2 (en)
EP (3) EP3909976A1 (en)
JP (4) JP6422883B2 (en)
KR (2) KR102254978B1 (en)
CN (2) CN110041432B (en)
AU (1) AU2013204922B2 (en)
CA (2) CA2895840C (en)
ES (2) ES2864507T3 (en)
HK (1) HK1215267A1 (en)
IL (1) IL239500B (en)
SG (2) SG11201504855WA (en)
WO (1) WO2014100385A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3626741A1 (en) 2013-02-20 2020-03-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
IL300508A (en) * 2013-03-15 2023-04-01 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
EP3623380A1 (en) * 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
RS60106B1 (en) 2014-04-25 2020-05-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
NZ726989A (en) 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
WO2015188141A2 (en) 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
CA2954414A1 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
TWI750110B (en) 2014-07-21 2021-12-21 瑞士商諾華公司 Treatment of cancer using humanized anti- bcma chimeric antigen receptor
MX2017001013A (en) 2014-07-21 2018-02-21 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor.
US20170226216A1 (en) * 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
JP6810685B2 (en) * 2014-09-04 2021-01-06 セレクティスＣｅｌｌｅｃｔｉｓ Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptor for cancer immunotherapy
DK3575315T3 (en) * 2014-09-15 2022-12-19 Molmed Spa CHIMERIC ANTIGEN RECEPTORS
EP3536707A1 (en) * 2014-11-05 2019-09-11 Board of Regents, The University of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
KR20170135824A (en) * 2015-01-26 2017-12-08 셀렉티스 T cell receptor knockout engineered immune cells that are believed to have chimeric antigen receptors that bind to CD123 for the treatment of dendritic cell neoplasms or recurrent / intractable acute myelogenous lymphoma of germ plasm cells.
KR101755431B1 (en) 2015-02-02 2017-07-12 단국대학교 산학협력단 CTLA-4 targeting trans-splicing ribozyme for delivering chimeric antigen receptor and use thereof
CN105985444B (en) * 2015-02-05 2024-02-13 博生吉安科细胞技术有限公司 Chimeric antigen receptor, and method and application for rapidly constructing chimeric antigen receptor
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
AU2016225012B2 (en) 2015-02-27 2020-09-03 Kevin Chen Chimeric antigen receptors (CARS) targeting hematologic malignancies, compositions and methods of use thereof
KR102133857B1 (en) * 2015-03-02 2020-07-20 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 Reduction of immune tolerance induced by PDD-L1
WO2016149682A2 (en) * 2015-03-18 2016-09-22 Memorial Sloan-Kettering Cancer Center Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies
JP2018510652A (en) * 2015-03-18 2018-04-19 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ HER2 / ERBB2 chimeric antigen receptor
CN115058395A (en) 2015-06-25 2022-09-16 美商生物细胞基因治疗有限公司 Chimeric Antigen Receptors (CAR), compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
MX2018000278A (en) * 2015-06-29 2018-03-08 Univ Johns Hopkins Immune checkpoint chimeric antigen receptors therapy.
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
SG11201800872QA (en) 2015-08-05 2018-03-28 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
KR20180083874A (en) 2015-11-04 2018-07-23 사울 제이. 프라이스맨 The chimeric antigen receptor targeting HER2
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
UA125252C2 (en) * 2016-01-21 2022-02-09 Пфайзер Інк. Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
CN105567640A (en) * 2016-01-27 2016-05-11 苏州佰通生物科技有限公司 Chimeric antigen receptor adipose-derived stem cell and preparation method thereof
IL287889B2 (en) * 2016-02-05 2024-03-01 Hope City Administration of engineered t cells for treatment of cancers in the central nervous system
WO2017139975A1 (en) * 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
CN105647946B (en) * 2016-03-18 2019-09-20 江苏普瑞康生物医药科技有限公司 A kind of mosaic gene and application thereof based on III a of Fc γ R
ES2962588T3 (en) * 2016-03-23 2024-03-20 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh PD-1 and 4-1BB fusion proteins
US20200283534A1 (en) * 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
CN106279432B (en) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 A kind of VC-CAR molecule and the application in removing HIV-1 infection cell
CN109983027A (en) 2016-10-20 2019-07-05 细胞基因公司 Based on CEREBLON can heterodimerization Chimeric antigen receptor
MX2019007404A (en) 2016-12-23 2019-09-27 Macrogenics Inc Adam9-binding molecules, and methods of use thereof.
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US10988754B2 (en) 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
CN107400168B (en) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 Chimeric antigen receptor based on CD117 and application thereof
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MX2020004572A (en) * 2017-11-01 2020-10-07 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen (bcma).
BR112020013910A2 (en) * 2018-01-08 2020-12-01 H. Lee Moffitt Cancer Center And Research Institute Inc. compositions and methods for targeting cancers that express cd99
EP3737692A4 (en) * 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
CN112601546B (en) * 2018-06-12 2024-04-16 湖南远泰生物技术有限公司 PLAP-CAR-effector cells
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112203725A (en) 2018-06-13 2021-01-08 诺华股份有限公司 BCMA chimeric antigen receptors and uses thereof
WO2020006568A1 (en) * 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
CN109096405B (en) * 2018-09-20 2021-07-09 杭州普略生物科技有限公司 Chimeric antigen receptor taking GD2 as target and pharmaceutical composition
JP2022519154A (en) * 2018-12-07 2022-03-22 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド Compositions and Methods for Immunotherapy
EP3894011A1 (en) 2018-12-11 2021-10-20 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
EP3935159A1 (en) 2019-03-08 2022-01-12 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252405A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
AU2020307673A1 (en) * 2019-06-27 2022-01-20 Eutilex Co., Ltd. Chimeric antigen receptor with 4-1BB costimulatory domain
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
CN110590960B (en) * 2019-09-26 2020-08-28 武汉波睿达生物科技有限公司 Chimeric antigen receptor with CD99 as target and application thereof
TW202309071A (en) 2021-05-05 2023-03-01 德商英麥提克生物技術股份有限公司 Antigen binding proteins specifically binding prame

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
JPH07291996A (en) * 1994-03-01 1995-11-07 Yuu Honshiyo Polypeptide related to programmed cell death in human, dna coding the same, vector consisting of the same dna, host cell transformed with the same vector, antibody of the same polypeptide and pharmaceutical composition containing the same polypeptide or the same antibody
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013584A1 (en) * 1994-11-01 1996-05-09 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
PT925294E (en) 1996-07-24 2003-04-30 Celgene Corp SUBSTITUTED 2- (2,6-DIOXOPIPERIDIN-3-YL) -FTALIMIDES AND -1-OXOISOINDOLINS AND REDUCTION METHOD OF TNF-ALFA LEVELS
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
CA2262906C (en) 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
ATE321803T1 (en) 1999-04-16 2006-04-15 Univ Wm Marsh Rice FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE-CO-ETHYLENE GLYCOL
GB9908816D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Biological product
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
AU778698B2 (en) 1999-04-29 2004-12-16 Miltenyi Biotec B.V. & Co. KG Method and means for producing high titer, safe, recombinant lentivirus vectors
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
KR20030032922A (en) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2002045174A (en) 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res Method for proliferating natural killer cell
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
ATE338124T1 (en) 2000-11-07 2006-09-15 Hope City CD19-SPECIFIC TARGETED IMMUNE CELLS
DK1349918T3 (en) 2000-12-06 2014-11-10 Anthrogenesis Corp Method of collecting stem cells from placenta
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
EP2336299A1 (en) 2001-02-14 2011-06-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP2004113062A (en) 2002-09-25 2004-04-15 Teruyuki Nagamune Animal cell having chimera receptor and its utilization
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
JP4790413B2 (en) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド Antibody therapy
GB0225279D0 (en) 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
JP2006521325A (en) 2003-03-24 2006-09-21 タップ ファーマシューティカル プロダクツ インコーポレイテッド Novel use of chemokine receptor agonists for stem cell transplantation
US7541442B2 (en) 2003-05-30 2009-06-02 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US20050118185A1 (en) 2003-06-18 2005-06-02 Cell Center Cologne Gmbh Recombinant immunoreceptors
AU2004260936B2 (en) 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
DK1720569T3 (en) 2004-02-27 2015-02-02 Immune System Therapeutics Ltd Targets for B-cell disorders
JP2005336062A (en) 2004-05-24 2005-12-08 Mitsubishi Chemicals Corp Homing inducer of t cell to intestinal tissue
FR2872170B1 (en) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
ES2711278T3 (en) 2005-12-29 2019-04-30 Celularity Inc Populations of placental stem cells
JP2009525048A (en) 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー Polypeptide-nucleic acid complex for immunological prophylaxis or immunotherapy against neoplastic disorders or infections
CN101563104A (en) 2006-02-01 2009-10-21 约翰霍普金斯大学 Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
ES2595307T3 (en) 2007-01-31 2016-12-29 Yeda Research And Development Company Limited Redirected, genetically modified regulatory T cells and their use in the suppression of autoimmune and inflammatory diseases
US8415154B2 (en) 2007-05-29 2013-04-09 Trustees Of Dartmouth College Compositions and methods for producing adaptive regulatory T cells
JP2010531638A (en) 2007-06-12 2010-09-30 ケース ウエスタン リザーブ ユニバーシティ Targeted cell death
EP2006376A1 (en) 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
KR101644659B1 (en) 2007-09-26 2016-08-01 안트로제네시스 코포레이션 Angiogenic cells from human placental perfusate
EP3524253A1 (en) 2007-09-28 2019-08-14 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2010003002A2 (en) 2008-07-02 2010-01-07 Board Of Regents, The University Of Texas System Modulation of follicular helper t cells
PL3006459T3 (en) 2008-08-26 2022-01-17 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
ES2633470T3 (en) 2008-09-22 2017-09-21 Baylor College Of Medicine Methods and compositions of generating an immune response by inducing CD40 and pattern recognition receptor adapters
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
US20120207744A1 (en) 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011035018A2 (en) 2009-09-18 2011-03-24 Fate Therapeutics, Inc. Suicide ready cells
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
MX337169B (en) 2010-02-11 2016-02-16 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same.
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20110287038A1 (en) 2010-04-16 2011-11-24 Kevin Slawin Method for treating solid tumors
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
CN103097520B (en) 2010-07-13 2017-12-05 人类起源公司 The method for producing NK
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
CN103501816A (en) 2010-10-27 2014-01-08 贝勒医学院 Chimeric CD27 receptors for redirecting t cells to CD70-positive malignancies
BR122021026173B1 (en) * 2010-12-09 2023-12-05 The Trustees Of The University Of Pennsylvania PHARMACEUTICAL COMPOSITION
EP2665521A4 (en) 2011-01-18 2014-09-03 Univ Pennsylvania Compositions and methods for treating cancer
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
JP6066991B2 (en) 2011-04-08 2017-01-25 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Methods for reversing the effects of tumor microenvironment using chimeric cytokine receptors
CN103596981B (en) 2011-04-08 2017-06-16 美国卫生和人力服务部 Anti-epidermal growth factor receptor variant III Chimeric antigen receptors and its purposes for treating cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
BR112014008849A2 (en) 2011-10-20 2017-09-12 Us Health chimeric anti-cd22 antigen receptors
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013188427A1 (en) 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
CN103483452B (en) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 Dual signal independent chimeric antigen receptors and uses thereof
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
MX2015001871A (en) 2012-08-13 2015-09-21 Anthrogenesis Corp Natural killer cells and uses thereof.
WO2014037422A1 (en) 2012-09-04 2014-03-13 Inven2 As Selective and controlled expansion of educated nk cells
NZ746914A (en) 2012-10-02 2020-03-27 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014214850C1 (en) 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
US9393268B2 (en) 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
EP3623380A1 (en) 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
WO2014197638A2 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
JP6870988B2 (en) 2014-02-24 2021-05-19 セルジーン コーポレイション How to use cereblon activators for neuronal amplification and treatment of central nervous system disorders
JP6778114B2 (en) 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Imid-based proteolysis modulators and related uses
JP2017525340A (en) 2014-07-07 2017-09-07 ターガザイム，アイエヌシー． Production and cryopreservation of fucosylated cells for therapeutic use
US20180080008A1 (en) 2014-08-12 2018-03-22 Anthrogenesis Corporation Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
AU2015374062B2 (en) 2014-12-31 2021-05-06 Celgene Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
CN117886949A (en) 2015-02-24 2024-04-16 加利福尼亚大学董事会 Transcription switch combined with triggering and using method thereof
CN109983027A (en) 2016-10-20 2019-07-05 细胞基因公司 Based on CEREBLON can heterodimerization Chimeric antigen receptor
US20200261501A1 (en) 2016-11-04 2020-08-20 Bluebird Bio, Inc. Anti-bcma car t cell compositions
SG11202100160SA (en) 2018-07-11 2021-02-25 Celgene Corp Uses of anti-bcma chimeric antigen receptors

Also Published As

Publication number Publication date
CN105246912A (en) 2016-01-13
WO2014100385A1 (en) 2014-06-26
CA2895840A1 (en) 2014-06-26
EP2935321B1 (en) 2018-09-26
AU2013204922A1 (en) 2014-07-10
US11130820B2 (en) 2021-09-28
AU2013204922B2 (en) 2015-05-14
CN110041432B (en) 2023-12-05
KR102361886B1 (en) 2022-02-14
IL239500A0 (en) 2015-08-31
EP2935321A1 (en) 2015-10-28
US20220106404A1 (en) 2022-04-07
CN110041432A (en) 2019-07-23
CA3178119A1 (en) 2014-06-26
ES2703747T3 (en) 2019-03-12
ES2864507T3 (en) 2021-10-13
US20190119399A1 (en) 2019-04-25
IL239500B (en) 2020-04-30
EP3483177B1 (en) 2021-02-24
CA2895840C (en) 2023-01-10
EP3909976A1 (en) 2021-11-17
KR102254978B1 (en) 2021-05-21
JP6697026B2 (en) 2020-05-20
HK1215267A1 (en) 2016-08-19
US10150816B2 (en) 2018-12-11
NZ749028A (en) 2020-12-18
US20150307623A1 (en) 2015-10-29
JP2020125334A (en) 2020-08-20
JP6992117B2 (en) 2022-02-03
EP3483177A1 (en) 2019-05-15
EP2935321A4 (en) 2016-07-06
KR20210059027A (en) 2021-05-24
KR20150099576A (en) 2015-08-31
JP2016507499A (en) 2016-03-10
JP6422883B2 (en) 2018-11-21
CN105246912B (en) 2019-05-03
SG11201504855WA (en) 2015-07-30
JP2018172388A (en) 2018-11-08
NZ709253A (en) 2020-09-25
JP2022033930A (en) 2022-03-02

Similar Documents

Publication Publication Date Title
SG10201805411YA (en) Chimeric antigen receptors
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
NZ754730A (en) Anti-icos agonist antibodies and uses thereof
SG10201914109VA (en) Novel anti-pd-1 antibodies
MX2022006006A (en) Immunomodulatory fusion proteins and uses thereof.
MX2019010812A (en) Immunomodulatory fusion proteins and uses thereof.
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MX2019011514A (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy.
MX366854B (en) AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES.
EA202090931A3 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS
MX2018001530A (en) Novel anti-pd-l1 antibodies.
MX2018013738A (en) Antibodies comprising chimeric constant domains.
MX2019000641A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use.
NZ737844A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
NZ712693A (en) Compositions and methods for immunotherapy
NZ714549A (en) Targeted/immunomodulatory fusion proteins and methods for making same
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
EP3839049A3 (en) Antibodies, variable domains & chains tailored for human use
IN2014CN03892A (en)
EP3508215A3 (en) Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2014026054A3 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
MX2014000054A (en) Anti-alpha synuclein binding molecules.
MX347515B (en) Frizzled-binding agents and uses thereof.
WO2010042890A3 (en) Polypeptides that bind trail-ri and trail-r2
PL2919801T3 (en) Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept